NZ755744A - Peptides and methods for the treatment of diabetes - Google Patents

Peptides and methods for the treatment of diabetes

Info

Publication number
NZ755744A
NZ755744A NZ755744A NZ75574418A NZ755744A NZ 755744 A NZ755744 A NZ 755744A NZ 755744 A NZ755744 A NZ 755744A NZ 75574418 A NZ75574418 A NZ 75574418A NZ 755744 A NZ755744 A NZ 755744A
Authority
NZ
New Zealand
Prior art keywords
diabetes
peptides
treatment
methods
cells
Prior art date
Application number
NZ755744A
Inventor
Elst Luc Vander
Vincent Carlier
Jean-Marie Saint-Remy
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of NZ755744A publication Critical patent/NZ755744A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG comprising a redox motif, the linker SLQP, and an insulin T cell epitope. Use of said peptides in treating type 1 diabetes and generating cytolytic CD4+ T cells is also disclosed. Use of the generated cytolytic T cells in treatment of type 1 diabetes is disclosed.
NZ755744A 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes NZ755744A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (1)

Publication Number Publication Date
NZ755744A true NZ755744A (en) 2023-07-28

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ755744A NZ755744A (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (en)
EP (1) EP3592765A1 (en)
JP (2) JP7102430B2 (en)
KR (1) KR20190126798A (en)
CN (1) CN110536898B (en)
AU (2) AU2018229741B2 (en)
BR (1) BR112019018616A2 (en)
CA (1) CA3051518A1 (en)
CO (1) CO2019009080A2 (en)
CU (1) CU24596B1 (en)
IL (1) IL268874B2 (en)
MX (1) MX2019010558A (en)
MY (1) MY192295A (en)
NZ (1) NZ755744A (en)
PE (1) PE20191529A1 (en)
PH (1) PH12019502036A1 (en)
RU (1) RU2761653C2 (en)
SA (1) SA519410007B1 (en)
SG (1) SG11201908275XA (en)
WO (1) WO2018162498A1 (en)
ZA (1) ZA201905851B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (en) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
AU2009214040B2 (en) * 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Strategies to prevent and/or treat immune responses to soluble allofactors
WO2018162498A1 (en) 2017-03-09 2018-09-13 Imcyse Sa Peptides and methods for the treatment of diabetes
US20230136112A1 (en) 2019-11-27 2023-05-04 Imcyse Sa Methods for stratifying diabetes patients
CN115916805A (en) 2020-05-06 2023-04-04 易姆赛斯股份公司 Immunogenic peptides with extended oxidoreductase motifs
AU2021208602A1 (en) * 2020-05-06 2022-12-15 Imcyse Sa Combination treatment for fumarate-related diseases
EP4347020A1 (en) 2021-06-01 2024-04-10 Imcyse SA Improved methods of treatment using immunogenic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316610A (en) * 2005-09-22 2008-12-03 艾润·R·科恩 Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
ES2657480T3 (en) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
AU2009214040B2 (en) 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Strategies to prevent and/or treat immune responses to soluble allofactors
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
CA2715484C (en) 2008-02-14 2017-04-11 Life Sciences Research Partners Vzw Suppression of immune responses to viral vectors
ES2650236T3 (en) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw CD4 + T lymphocytes with cytolytic properties
UY33297A (en) 2010-03-29 2011-09-30 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT UNDERSTANDS AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
MX2016005822A (en) * 2013-11-04 2016-12-02 Uti Limited Partnership Methods and compositions for sustained immunotherapy.
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
WO2018162498A1 (en) * 2017-03-09 2018-09-13 Imcyse Sa Peptides and methods for the treatment of diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (en) 2019-11-11 2020-04-11 競泰股份有限公司 Multiple keys lock core

Also Published As

Publication number Publication date
AU2021277735A1 (en) 2021-12-23
CA3051518A1 (en) 2018-09-13
US20220411476A1 (en) 2022-12-29
US20240092843A1 (en) 2024-03-21
US11407795B2 (en) 2022-08-09
JP7102430B2 (en) 2022-07-19
CN110536898B (en) 2023-09-08
BR112019018616A2 (en) 2020-04-28
US20200407406A1 (en) 2020-12-31
IL268874B2 (en) 2023-09-01
CN110536898A (en) 2019-12-03
ZA201905851B (en) 2021-04-28
RU2019126232A3 (en) 2021-06-01
IL268874B1 (en) 2023-05-01
RU2761653C2 (en) 2021-12-13
RU2019126232A (en) 2021-04-10
CU24596B1 (en) 2022-05-11
EP3592765A1 (en) 2020-01-15
SA519410007B1 (en) 2023-02-16
CO2019009080A2 (en) 2019-08-30
WO2018162498A1 (en) 2018-09-13
JP2022125216A (en) 2022-08-26
KR20190126798A (en) 2019-11-12
AU2018229741B2 (en) 2021-09-02
PE20191529A1 (en) 2019-10-23
JP2020509067A (en) 2020-03-26
US11760782B2 (en) 2023-09-19
AU2018229741A1 (en) 2019-08-15
CU20190078A7 (en) 2020-04-02
PH12019502036A1 (en) 2020-06-15
MX2019010558A (en) 2019-10-21
US10808016B2 (en) 2020-10-20
IL268874A (en) 2019-10-31
US20190352348A1 (en) 2019-11-21
SG11201908275XA (en) 2019-10-30
MY192295A (en) 2022-08-17

Similar Documents

Publication Publication Date Title
NZ755744A (en) Peptides and methods for the treatment of diabetes
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2022001222A (en) Anti-tim-3 antibodies and methods of use thereof.
MX2019008413A (en) Immunoengineered pluripotent cells.
NZ765695A (en) Immune cell organoid co-cultures
MX2019012223A (en) Anti-cd137 antibodies and methods of use thereof.
PH12017500803A1 (en) Anti-pd-1 antibodies
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
MX2017002900A (en) Global gene therapy for treating hemoglobinopathies.
MX2018004515A (en) Antibody agents specific for human cd19 and uses thereof.
AU2017240801A8 (en) Chimeric receptors to FLT3 and methods of use thereof
MX2020010693A (en) Use of long-acting glp-1 peptides.
MA40057A (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
JO3092B1 (en) Composition for controlled ovarian stimulation
MX2017005134A (en) Treatment of cancer with immune stimulators.
MX2020011817A (en) Methods for treating lymphoma.
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2022002315A (en) Anti-cd96 antibodies and methods of use thereof.
MX2016009241A (en) Methods of reducing malodor and bacteria.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
MX2017002388A (en) Compositions for keratin fibers.
WO2018088694A3 (en) Artificially engineered sc function control system
MX2017012596A (en) A pharmaceutical composition and the use thereof.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX2019000677A (en) B-cell-mimetic cells.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 MAR 2025 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20240226